The anticipation surrounding dose optimization data for Pfizer (NYSE:PFE)'s obesity treatment, danuglipron, was also mentioned as a point of interest for the first quarter. However, the analyst ...

Global pharmaceutical company Pfizer (NYSE:PFE) reported Q4 CY2024 results , with sales up 21.9% year on year to $17.76 ...

Pfizer beats Q4 estimates with 24.9% revenue growth, reaffirming 2025 guidance and targeting $4.5 billion in cost savings ...

US pharma giant Pfizer reported financial results for fourth-quarter and full-year 2024 and reaffirmed its 2025 financial ...

Pfizer (PFE) is set to announce Q4 earnings, with analysts expecting a $0.46 profit per share and $17.26B revenue.

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows ...

Pfizer Inc. (NYSE: PFE) shares are trading lower Tuesday after the Senate Finance Committee voted to advance Robert F. Kennedy Jr.'s nomination for Secretary of Health and Human Services.

Strong Covid product sales and cost-cutting initiatives drove Pfizer's $17.76 billion in revenue in Q4, exceeding Wall Street ...

Bourla outlined 2025 priorities, which include improving R&D productivity, achieving margin expansion, and maintaining commercial excellence. He highlighted expectations for nine Phase 3 readouts, 13 ...

CEO Albert Bourla says Pfizer has met the strategic goals it had set for itself in 2024, and that it was ‘executing transformative changes.’ ...

Despite a significant year-over-year decline in Comirnaty revenue, the overall performance was strong, driven by growth in non-COVID-19 products and strategic acquisitions. Pfizer, a renowned ...

The CEO said last month that the drugmaker had cut costs, revamped its sales operation, and made other big fixes.